Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3 HKD -0.66% Market Closed
Market Cap: 2B HKD

Operating Margin
Antengene Corporation Ltd

-346.6%
Current
-862%
Average
7.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-346.6%
=
Operating Profit
-318.7m
/
Revenue
92m

Operating Margin Across Competitors

Antengene Corporation Ltd
Glance View

Market Cap
2B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 40%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-346.6%
=
Operating Profit
-318.7m
/
Revenue
92m
What is the Operating Margin of Antengene Corporation Ltd?

Based on Antengene Corporation Ltd's most recent financial statements, the company has Operating Margin of -346.6%.

Back to Top